Wu Yifang, president and CEO of Shanghai Fosun Pharmaceutical Group. Photo: Handout
China’s Fosun Pharma to bypass India’s regulatory hurdles after cutting stake in Gland Pharma deal
Chinese drug maker to cut the stake it wants to buy in India’s Gland Pharma to ensure faster regulatory approvals
Updated: Friday, 20 Jul, 2018 2:55pm
TOP PICKS
Wu Yifang, president and CEO of Shanghai Fosun Pharmaceutical Group. Photo: Handout
READ FULL ARTICLE
SCMP TODAY: INTL EDITION
Get updates direct to your inbox
By registering for these newsletters you agree to our T&C and Privacy Policy
Products & Services
About Us
DOWNLOAD THE SCMP APP
Copyright © 2019 South China Morning Post Publishers Ltd. All rights reserved.
0
Share